Pfizer and BioNTech’s COVID-19 vaccine protected just 12 percent of children aged five to 11 against COVID-19 infection, according to a study conducted by the New York State Department of Health.
The study focused on how the vaccine protected children against the Omicron variant of the virus during the strain’s December 13th through January 24th surge. The 12 percent figure – which translates to the vaccine conferring roughly one in 10 children with protection against the variant – comes amidst several states and schools rolling out vaccine mandates for kids.
“During Omicron variant predominance, vaccine effectiveness against infection declined rapidly for New York State children 5- 11 years, with low protection by one month following full-vaccination. Among children 12-17, protection declined substantially, albeit more slowly than observed among younger children,” explained the study, which is still awaiting peer review.
“From December 13th, 2021 to January 30th, 2022, among 852,384 fully-vaccinated children 12 to 17 years and 365,502 children 5 to 11 years, vaccine effectiveness against cases declined from 66 percent to 51 percent for those 12 to 17 years and from 68 percent to 12 percent for those 5 to 11 years,” the paper, which used data from hospitals across the state, continued.
From January 24th to January 30th, vaccine effectiveness for 11 year olds dipped down to just 11 percent.
“Our data support vaccine protection against severe disease among children 5-11 years, but suggest rapid loss of protection against infection, in the Omicron variant era. Should such findings be replicated in other settings, review of the dosing schedule for children 5-11 years appears prudent.”
The Pfizer vaccine’s lack of protection also follows the company sizably expanding its efforts lobbying the federal government in terms of personnel and overall money spent.
Criticism of the company’s COVID-19 vaccine has also been routinely censored by social media “fact checking” operations and mainstream media outlets, which have repeatedly proven to have conflicts of interest with the pharmaceutical firm.